Certain Warrants of Virios Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAR-2023.
March 18, 2023
Share
Certain Warrants of Virios Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAR-2023. These Warrants will be under lockup for 181 days starting from 19-SEP-2022 to 19-MAR-2023.
Details:
Each of its directors and officers as of the date of this prospectus have agreed for a period of six months in the case of such directors and officers after the date of this prospectus, without the prior written consent of the representative, not to directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for common stock or other capital stock.
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.